

control

u'

type
2.5 to 5
N/A

same meaning as in Claim 1,1

R is hydroxy, lower alkoxy or NH₂;

R₁ and R₄ each is hydrogen, lower
alkyl or phenyl-lower alkyl;

R₂ is hydrogen or R₅-CO;

R₃ is hydrogen, hydroxy or lower
alkyl;

R₅ is lower alkyl, phenyl or phenyl-
lower alkyl; and

n is 0, 1 or 2,

about [15] 2.5 to 300 mg. of a diuretic selected from the group consisting of chlorothiazide, hydrochlorothiazide, amiloride, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylclothiazide, trichlormethiazide, polythiazide, benzthiazide, ethacrynic acid, ticrynafen, chlorthalidone, furosemide, bumetanide, triamterene, spironolactone and salts thereof, and a physiologically acceptable carrier therefor.

REMARKS

The purposes of this Amendment are to amend the specification and claims to indicate the current status of the parent application; to amend the ratio of medicaments to an upper limit of 40:1, rather than 12:1, for consistency, as more fully detailed hereinafter; to amend Claim 1 (and hence dependent Claims 4 through 8) to recite a daily dosage of the range of medicaments currently recited in Claim 2; to cancel Claim 2 since it is now redundant; to amend Claim 10 so that it now depends from Claim 1, rather than cancelled Claim 2; and to amend Claim 13 to define the substituents independent of Claim 1 and to broaden the range of ingredients